Showing posts with label Cancer. Show all posts
Showing posts with label Cancer. Show all posts

Wednesday, August 10, 2022

Belgium pulls more Haagen-Dazs ice-creams from sale

BRUSSELS - Belgium on Tuesday extended an order to recall certain Haagen-Dazs ice-creams from sale after the discovery of traces of a chemical linked to cancer, such as lymphoma and leukemia. 

The move was triggered by an EU food safety alert and Spain and France have also issued recalls of several Haagen-Dazs products.

After already recalling 10 products last Friday, the Belgian national food health agency added seven more Haagen-Dazs products to the list on Tuesday. 

The latest move concerns tubs and minicups made by Haagen-Dazs, a brand owned by US manufacturer General Mills, with use-by dates of between March and April 2023, with flavours including Vanilla, Belgian Chocolate, Macadamia Nut Brittle and Pralines & Cream.

Customers who had bought Haagen-Dazs products affected by the recalls were told not to eat them, destroy them and to contact General Mills for a refund.

The alert was relayed on the EU's Rapid Alert System for Food and Feed system at the request of France, which last month detected 2-Chloroethanol in checks on some Haagen-Dazs products, triggering the initial recall.

2-Chloroethanol is a compound found in ethylene oxide (ETO), a carcinogenic chemical used as a pesticide and cleaning chemical, and has properties that damage DNA. 

General Mills said last week that "trace levels of ETO can be sourced to one ingredient (vanilla extract) provided by one of our suppliers".

Outside the EU, Brazil's ANVISA health monitoring agency last month issued its own alert over vanilla Haagen-Dazs products imported from France.

Despite its name, Haagen-Dazs does not have Nordic origins. It was founded by a Polish-Jewish couple in New York who gave it a brand they thought sounded Danish.

Agence France-Presse

Sunday, December 13, 2020

AstraZeneca to buy Alexion for $39 billion to expand in immunology

FRANKFURT - Britain's AstraZeneca has agreed to buy US drugmaker Alexion Pharmaceuticals for $39 billion in its largest ever deal, diversifying away from its fast-growing cancer business in a bet on rare-disease and immunology drugs.

The deal comes in a week that AstraZeneca said it was conducting further research to confirm whether its COVID-19 vaccine could be 90% effective, potentially slowing its rollout, and as a rival shot from Pfizer was launched in Britain and approved for use in the United States.

The British company said on Saturday that Alexion shareholders would receive $60 in cash and about $115 worth of equity per share - either in AstraZeneca's UK-traded ordinary shares or in dollar-denominated American Depositary Shares.

Based on a reference average ADR price of $54.14, that implies a total price of $175 per share. Alexion shares closed at around $121 apiece on Friday.

"It is a tremendous opportunity for us to accelerate our development in immunology, getting into a new segment of disease, a new segment of physicians, and patients we haven’t been able to cover so far," AstraZeneca Chief Executive Pascal Soriot told a media call.

Alexion's best-selling drug is Soliris, used against a range of rare immune-disorders including paroxysmal nocturnal hemoglobinuria (PNH), which causes anaemia and blood clots, and whose revenue rose 3.6% in the first nine months to $3 billion.

AstraZeneca hopes that an improved version of Soliris called Ultomiris has an even larger market potential. It expects more growth from introducing the target's rare-disease treatments to China and other emerging markets.

The British firm said the boards of both companies had approved the deal, which is expected to close in the third quarter of 2021.

AstraZeneca was once seen as leading the race to develop a COVID-19 vaccine, but has fallen behind Pfizer and its partner BioNTech, as well as Moderna, whose shots have shown greater efficacy in late-stage clinical trials.

With a planned capital increase of about $25 billion after the deal closure, Soriot is looking to harness a strong advance by AstraZeneca stock, driven by the stellar growth of new cancer drugs.

The shares have climbed about 70% through the past three years. A precursor cash call, on a much smaller scale, was a $3.5 billion issue last year to fund the purchase of rights to cancer drug Enhertu from Daiichi Sankyo.

RARE DISEASES

Despite generating billions in cash from treatments such as Soliris, one of the most expensive drugs in the world costing hundreds of thousands of dollars per patient, Alexion shares have struggled in recent years as investors have worried about competition heating up.

That had led it to be seen as a possible bid target.

Hedge fund and activist investor Elliott Management has urged Alexion to seek a buyer and in May spoke out publicly.

The fund, which had held private meetings with the company, said CEO Ludwig Hantson’s go-it-alone approach had failed to gain traction and opposed its plan to buy rivals to diversify its research pipeline.

Elliott first invested in Alexion in 2017 when the share price was only slightly lower than Friday's close of $120.98. Elliott did not immediately respond to a request for comment.

AstraZeneca said it expected the deal to immediately boost core earnings and to deliver pretax synergy gains of around $500 million per year. It also expects around $650 million in one-time cash costs during the three years following completion.

Speaking on an analyst call, 61-year-old Soriot said the deal should put to rest speculation he was on his way out, as he was determined to stay on board to see the strategic benefits of the transaction delivered.

Soriot also told reporters the deal was the result of exclusive talks and no competitive bidder was involved.

AstraZeneca finance chief Marc Dunoyer said a capital increase for the equity component of the transaction would take place on closure of the deal.

On AstraZeneca's COVID-19 vaccine, Soriot said it wasn't yet clear if the company would need results from a U.S. clinical trial before filing for approval with U.S. regulators.

Assuming positive results from that trial, the company should be able to submit the vaccine to US regulators within the next six weeks, he added. 

-reuters-

Monday, November 9, 2020

LOS ANGELES — Game show host Alex Trebek, who as the brainy quizmaster of “Jeopardy!” became one of the most recognizable personalities on American television, died on Sunday at the age of 80, the show said on its official Twitter account.

The Canadian-born Trebek said in a YouTube video in March 2019 that he had been diagnosed with Stage 4 pancreatic cancer, vowing to beat the disease despite the long odds.

Trebek told fans in August 2019 he had completed chemotherapy, but he disclosed the following month that he had to restart treatment because of a setback.

He passed away peacefully at home surrounded by family and friends, the show’s tweet said.

Twenty years after “Jeopardy!” first aired in 1964, Trebek became the face of the show and turned it into a ratings powerhouse.

“Jeopardy!” which requires contestants to display their knowledge of a broad range of trivia topics by providing their answers in the form of a question, has consistently drawn more than 20 million viewers a week in the United States and Canada, making it the most-watched quiz show in those markets.

Its ratings have risen even higher when contestants have racked up several weeks of consecutive wins.

“Here’s the belief that lies at the core of Alex’s TV persona: ‘Jeopardy!’ itself, not he, is the star of the show,” Ken Jennings, a former “Jeopardy!” contestant who holds the record for the longest winning streak on the show, said of Trebek in a 2019 column in the New York Times.

“It’s hard to imagine any modern TV personality deftly avoiding the spotlight like that,” Jennings added.

Trebek was known for engaging contestants with straight-faced but witty banter and for his scholarly demeanor and scrupulous pronunciation.

Jennings compared Trebek, who hosted more than 7,000 episodes of “Jeopardy!” with the late news anchor Walter Cronkite and talk-show host Johnny Carson because his nightly presence on television had become a “matter of ritual.”

Trebek won six Emmy Awards for outstanding game-show host, most recently in 2019, and also received a Lifetime Achievement Emmy in 2011. The Hollywood Reporter said in a 2014 article that Trebek was earning $10 million a year.


Canada to California


Trebek was born in the nickel-mining city of Sudbury, Ontario, the son of a Ukrainian immigrant father and a French-Canadian mother.

He earned a degree in philosophy at the University of Ottawa, beginning his career in broadcasting while still attending school.

After hosting a number of television shows in Canada during the 1960s, Trebek was encouraged to move to California in 1973 by the late actor Alan Thicke, a fellow Canadian, to host a short-lived NBC game show called “The Wizard of Odds.”

In the following years, Trebek hosted a few other shows with equally quirky names, such as “High Rollers” and “Battlestars.”

None of them became an enduring success but they bolstered Trebek’s reputation in Hollywood and eventually paved the way for his joining “Jeopardy!”

Television personality Merv Griffin, along with his wife, Julann, came up with the idea for “Jeopardy! in the 1960s.”

Art Fleming, who died in 1995, served as the show’s original host in its initial run from 1964 to 1975 and in a 1978-79 revival.

When Griffin revived “Jeopardy!” again after a hiatus of several years, producers chose Trebek to host it and Trebek also helped produce the show for his first three seasons.

One of the gigs that helped him secure the position was a temporary role on “Wheel of Fortune,” another game show Griffin had created, according to an interview Trebek gave in 2007.

Viewers became oddly attached to the mustache Trebek sported from early in his career until he shaved it off in 2001. It made headlines when he grew back the mustache in 2014.

Trebek is survived by his wife, Jean, and their two adult children, Emily and Matthew.

-reuters-



Saturday, August 29, 2020

Shock, grief, and gratitude after death of Chadwick Boseman


“He was a gentle soul and a brilliant artist, who will stay with us for eternity through his iconic performances over his short yet illustrious career. God bless Chadwick Boseman.” — Denzel Washington, via a statement.

“Chadwick.....no words to express my devastation of losing you. Your talent, your spirit, your heart, your authenticity........It was an honor working beside you, getting to know you....Rest well prince...May flights of angels sing thee to thy heavenly rest. I love you!” — Viola Davis, co-star in “Get on Up” and the upcoming adaptation of August Wilson’s “Ma Rainey’s Black Bottom,” via Instagram.

“During the premiere party for Black Panther, Chadwick reminded me of something. He whispered that when I received my honorary degree from Howard University, his alma mater, he was the student assigned to escort me that day. And here we were, years later as friends and colleagues, enjoying the most glorious night ever! We’d spent weeks prepping, working, sitting next to each other every morning in makeup chairs, preparing for the day together as mother and son. I am honored that we enjoyed that full circle experience. This young man’s dedication was awe-inspiring, his smile contagious, his talent unreal. So I pay tribute to a beautiful spirit, a consummate artist, a soulful brother...‘thou aren’t not dead but flown afar...’. All you possessed, Chadwick, you freely gave. Rest now, sweet prince.” — Angela Bassett, co-star in ”Black Panther,” via Instagram.

“I don’t have words. Rest In Peace, Bruh. Thank you for all you did while you were here. Thank you for being a friend. You are loved. You will be missed.” — Boseman’s “Black Panther” co-star Sterling K. Brown.

“I’m absolutely devastated. This is beyond heartbreaking. Chadwick was special. A true original. He was a deeply committed and constantly curious artist. He had so much amazing work still left to create. I’m endlessly grateful for our friendship. Rest in power, King.” — Chris Evans, who played Captain America in multiple Marvel films, via Twitter.

“What a man, and what an immense talent. Brother, you were one of the all time greats and your greatness was only beginning. Lord love ya. Rest in power, King.” — Mark Ruffalo, Boseman’s co-star in “Avengers: Infinity War” and “Avengers: Endgame,” via Twitter.

“THANK YOU @chadwickboseman for all you gave us. We needed it & will always cherish it! A talented & giving artist & brother who will be sorely missed.” — Samuel L. Jackson, co-star in “Avengers: Endgame”, via Twitter.

“This is a crushing blow.” — director and actor Jordan Peele on Twitter.

“Our hearts are broken and our thoughts are with Chadwick Boseman’s family. Your legacy will live on forever.” — Marvel Studios, via Instagram.


“Heartbroken. My friend and fellow Bison Chadwick Boseman was brilliant, kind, learned, and humble. He left too early but his life made a difference.” — Kamala Harris, on Twitter. Harris and Boseman were both graduates of Howard University, and his final tweet celebrated her selection as Joe Biden’s running mate.

“The true power of @ChadwickBoseman was bigger than anything we saw on screen. From the Black Panther to Jackie Robinson, he inspired generations and showed them they can be anything they want — even super heroes.” — Joe Biden, via Twitter.

“We are devastated by the tragic loss of Chadwick Boseman. His transcendent performance in ’42′ will stand the test of time and serve as a powerful vehicle to tell Jackie’s story to audiences for generations to come.” — Major League Baseball, via Twitter.

“This broke me.” — Actor and writer Issa Rae on Twitter.

“i will miss you, birthday brother. you were always light and love to me. my god.” Don Cheadle, via Twitter.

“So stunned. Honored to have worked with @chadwickboseman early on. Truly an amazing man. God bless his wife and family in this difficult time. Rest In Peace, brother.” — Terry Crews, via Twitter.

“A warrior of light til the very end. A true king. I am without words. May he rise in power.” — Actor Kerry Washington, on Twitter.

“I met you at the premier of 42 in Pittsburgh in 2013. Even though you were in the spotlight and all eyes were on you, I remember you saying, ‘I’m that one that’s starstruck by all of these athletes here.’ That’s the man you were. Humble. You will be missed.” — Philadelphia Phillies outfielder Andrew McCutchen, a former National League Most Valuable Player when he played for Pittsburgh, on Twitter.

“Just when you thought 2020 couldn’t get any worse... A deeply gifted man is gone too soon. His memory will blaze on fiercely... from here to eternity.” — Mark Hamill, on Twitter.

“Hard to hear about this. Rest in love, brother. Thank you for shining your light and sharing your talent with the world. My love and strength to your family.” — Dwayne Johnson, via Twitter.

“Our makeup artists are friends and he used to get on the phone and ask me to sing “You Mean The World To Me” because it was his favorite song of mine and now this song will be forever dedicated to him.” — Toni Braxton, recording artist, on Twitter.

“In power. Eternally in power.” — “Moonlight” director Barry Jenkins, via Twitter.

“We love you, Chadwick. Your legacy will never die.” — Lena Waithe, on Twitter.

“An immeasurable loss. From “Black Panther” to “Da 5 Bloods,” Chadwick Boseman brought strength and light to the screen, every time.” — The Academy of Motion Picture Arts and Sciences, via Twitter.

“We’ve lost a great one. My heart is truly broken.” — Octavia Spencer on Instagram.

Associated Press

Wednesday, April 29, 2020

Irrfan Khan, Indian actor in 'Life of Pi', dies after battling cancer


MUMBAI - Irrfan Khan, an Indian actor who brought a modern sensibility to recent hit films and had roles in Hollywood movies such as "Life of Pi" and "The Namesake," died on Wednesday, aged 54.

The death, after a prolonged battle with cancer, was confirmed by a spokesman who said Khan was surrounded by family at the time.

"He fought the many battles that came with it," the spokesman said in a statement, referring to the diagnosis of Khan's rare cancer in 2018.

Khan was among the first Indian actors to make a consistent mark in Western cinema, following in the footsteps of crossover pioneers such as Saeed Jaffrey, Roshan Seth and Om Puri.

Born Sahabzade Irfan Ali Khan in the western desert state of Rajasthan, in a family with no ties to cinema, the actor recalled in interviews that as children, he and his siblings were not allowed to watch movies.

The only exception was when a visiting uncle took them to the theater.

"An incredible talent," said Bollywood superstar Amitabh Bachchan, among the tributes on Twitter that followed Khan's death. "A gracious colleague. A prolific contributor to the world of cinema... left us too soon creating a huge vacuum."

Another well-known director, Karan Johar, said, "Thank you for raising the bar as an artist... Thank you for enriching our cinema... We will miss you terribly, Irrfan." 

-reuters-

Saturday, January 11, 2020

Neil Peart, Rush's star drummer, dies at 67


LOS ANGELES, United States - Neil Peart, the drummer and lyricist of Canadian rock group Rush, has died at 67 in California of brain cancer, the group announced Friday.

"It is with broken hearts and the deepest sadness that we must share the terrible news that on Tuesday, our friend, soul brother and band mate of over 45 years, Neil, has lost his incredibly brave battle with brain cancer, glioblastoma," they said in a statement posted on Twitter.

Rush was founded in 1968 and Peart joined in 1974, replacing John Rutsey, alongside singer and bass player Geddy Lee and guitarist Alex Lifeson.

After starting out in hard rock and moving gradually toward jazz rock, Peart was known for his flamboyant style and very precise technique, which won him a legion of admirers among professionals and fans.

Questlove, the drummer for hip-hop group The Roots, posted a black and white photo of Peart on Instagram sitting behind his imposing drum set, sending his condolences.

Danish drummer Lars Ulrich of Metallica also said on Instagram that Peart was a big inspiration for him.

Rush entered the Rock and Roll Hall of Fame in 2013. The band sold 25 million albums in the United States.

source: news.abs-cbn.com

Thursday, January 2, 2020

Study finds Google system could improve breast cancer detection


CHICAGO — A Google artificial intelligence system proved as good as expert radiologists at detecting which women had breast cancer based on screening mammograms and showed promise at reducing errors, researchers in the United States and Britain reported.

The study, published in the journal Nature on Wednesday, is the latest to show that artificial intelligence (AI) has the potential to improve the accuracy of screening for breast cancer, which affects one in eight women globally.

Radiologists miss about 20 percent of breast cancers in mammograms, the American Cancer Society says, and half of all women who get the screenings over a 10-year period have a false positive result.

The findings of the study, developed with Alphabet Inc's DeepMind AI unit, which merged with Google Health in September, represent a major advance in the potential for the early detection of breast cancer, Mozziyar Etemadi, one of its co-authors from Northwestern Medicine in Chicago, said.

The team, which included researchers at Imperial College London and Britain's National Health Service, trained the system to identify breast cancers on tens of thousands of mammograms.

They then compared the system's performance with the actual results from a set of 25,856 mammograms in the United Kingdom and 3,097 from the United States.

The study showed the AI system could identify cancers with a similar degree of accuracy to expert radiologists, while reducing the number of false positive results by 5.7 percent in the US-based group and by 1.2 percent in the British-based group. 

It also cut the number of false negatives, where tests are wrongly classified as normal, by 9.4 percent in the US group, and by 2.7 percent in the British group.

These differences reflect the ways in which mammograms are read. In the United States, only one radiologist reads the results and the tests are done every one to 2 years. In Britain, the tests are done every 3 years, and each is read by 2 radiologists. When they disagree, a third is consulted.

'SUBTLE CUES'

In a separate test, the group pitted the AI system against 6 radiologists and found it outperformed them at accurately detecting breast cancers.

Connie Lehman, chief of the breast imaging department at Harvard's Massachusetts General Hospital, said the results are in line with findings from several groups using AI to improve cancer detection in mammograms, including her own work.

The notion of using computers to improve cancer diagnostics is decades old, and computer-aided detection (CAD) systems are commonplace in mammography clinics, yet CAD programs have not improved performance in clinical practice.

The issue, Lehman said, is that current CAD programs were trained to identify things human radiologists can see, whereas with AI, computers learn to spot cancers based on the actual results of thousands of mammograms.

This has the potential to "exceed human capacity to identify subtle cues that the human eye and brain aren't able to perceive," Lehman added.

Although computers have not been "super helpful" so far, "what we've shown at least in tens of thousands of mammograms is the tool can actually make a very well-informed decision," Etemadi said.

The study has some limitations. Most of the tests were done using the same type of imaging equipment, and the US group contained a lot of patients with confirmed breast cancers.

Crucially, the team has yet to show the tool improves patient care, said Dr Lisa Watanabe, chief medical officer of CureMetrix, whose AI mammogram program won US approval last year.

"AI software is only helpful if it actually moves the dial for the radiologist," she said.

Etemadi agreed that those studies are needed, as is regulatory approval, a process that could take several years. 

source: news.abs-cbn.com

Saturday, October 19, 2019

J&J recalls 33,000 bottles of baby powder as FDA finds asbestos in sample


Johnson & Johnson said on Friday it is recalling around 33,000 bottles of baby powder in the United States after US health regulators found trace amounts of asbestos in samples taken from a bottle purchased online.

J&J shares fell more than 6 percent to close at $127.70.

The move marks the first time the company has recalled its iconic baby powder for possible asbestos contamination, and the first time US regulators have announced a finding of asbestos in the product. Asbestos is a known carcinogen that has been linked to deadly mesothelioma.

The recall is the latest blow to the more than 130-year-old US healthcare conglomerate that is facing thousands of lawsuits over a variety of products, including baby powder, opioids, medical devices and the antipsychotic Risperdal.

A jury last week ordered the company to pay $8 billion to a plaintiff in a case claiming J&J downplayed the risks of Risperdal. That award is not expected to stand, the company and legal experts have said.

J&J faces more than 15,000 lawsuits from consumers claiming its talc products, including Johnson's Baby Powder, caused their cancer.

On a conference call with reporters on Friday, Dr. Susan Nicholson, head of Women’s Health in the company's medical safety organization, called the asbestos finding "extremely unusual," adding that it was "inconsistent with our testing to date."

The voluntary recall announced on Friday is limited to one lot of Johnson's Baby Powder produced and shipped in the United States in 2018, the company said. 

J&J in a news release said that testing by the US Food and Drug Administration as recently as a month ago found no asbestos in their talc.

The FDA said in a statement that the latest sampling took place during its testing for asbestos in talc-containing cosmetics that it began reporting this year. A second Johnson’s Baby Powder sample from a different lot tested negative for asbestos, the agency said.

The FDA said it stands by the quality of its testing and results and recommended consumers stop using the product if it comes from the affected lot.

J&J said on the conference call that it received a report from the FDA on Oct. 17 alerting the company about the asbestos finding. It said it has started an investigation and is reviewing manufacturing records and collecting data on the distribution of the lot to determine where the product was shipped.

J&J added that it is working with the FDA to determine the integrity of the tested sample as well as the validity of test results.

THOROUGH INVESTIGATION NEEDED

The type of asbestos discovered by FDA testing has not been found in the mine where the company sources its talc, J&J's Nicholson said. She described it as an environmental contaminant most commonly found in building materials and industrial applications.

J&J said it was too early to confirm whether cross-contamination of the sample had caused a false positive, whether the sample was taken from a bottle with an intact seal or whether it was prepared in a controlled environment. It added that it could not confirm whether the tested product was authentic or counterfeit.

"It is so critical that we perform a thorough investigation of the sample to determine the source of contamination," Nicholson said.

Since 2003, talc in Johnson's Baby Powder sold in the United States has come from China through supplier Imerys Talc America, a unit of Paris-based Imerys SA and a co-defendant in much of the talc litigation. Imerys and J&J said the Chinese talc is safe.

J&J has known for decades that asbestos lurked in its talc, Reuters reported last year. Internal company records, trial testimony and other evidence show that from at least 1971 to the early 2000s, the company’s raw talc and finished powders sometimes tested positive for small amounts of asbestos. Company executives, mine managers, scientists, doctors and lawyers fretted over the problem and how to address it, while failing to disclose it to regulators or the public, Reuters found.

J&J has repeatedly said that its talc products are safe, and that decades of studies have shown them to be asbestos-free and that they do not cause cancer.

The FDA test indicated the presence of no greater than 0.00002 percent of chrysotile asbestos in the tested sample, J&J said.

The World Health Organization and other authorities recognize no safe level of exposure to asbestos. While most people exposed never develop cancer, for some, even small amounts of asbestos are enough to trigger the disease years later.

Thousands of the lawsuits against J&J have been consolidated before a New Jersey federal judge, who is currently weighing company motions to disqualify plaintiffs’ expert witnesses, including the head of an asbestos testing lab who has testified in earlier trials that he found the contaminant in J&J powders.

Leigh O’Dell, one of the lead plaintiff attorneys, on Friday said the recall "vindicates the position we’ve been taking for months.”

Wells Fargo analyst Larry Biegelsen said in a research note that the recall could encourage additional lawsuits and prompt the company to pursue a broader settlement.

Jefferies healthcare strategist Jared Holz said J&J has already lost close to $10 billion in market value due to the talc issue over the past year.

He said further downside to J&J stock is likely to be limited because legal concerns over talc are well known and have already taken a toll on the share price. "This is one single bottle within one lot with barely a trace here," he said.

J&J said in February that it had received subpoenas from the US Justice Department and the Securities and Exchange Commission for documents related to the asbestos contamination allegations. A Bloomberg report, which Reuters has confirmed, said those inquiries include a criminal grand jury investigation into how forthright J&J has been in its statements about the safety of its powders.

While talc products make up less than 1 percent of J&J sales expected by analysts to reach $82 billion in 2019, the New Jersey-based healthcare-products maker considers its Baby Powder to be an essential facet of a carefully tended image as a caring company.

source: news.abs-cbn.com

Wednesday, October 9, 2019

GSK recalls popular heartburn drug Zantac globally after cancer scare


GlaxoSmithKline on Tuesday said it was recalling the popular heartburn medicine Zantac in all markets as a "precaution", days after the US Food and Drug Administration found "unacceptable" levels of probable cancer-causing impurity in the drug.

Zantac, also sold generically as ranitidine, is the latest drug in which cancer-causing impurities have been found. Regulators have been recalling some blood pressure and heart failure medicines since last year.

Britain's medicines watchdog said GlaxoSmithKline (GSK) was recalling four prescription-only Zantac medicines: a syrup, an injection and tablets of 150 and 300 milligram (mg) dosages.

Over-the-counter 75 mg dosage Zantac products are produced by a different company and are not affected by the recall, it added.

"GSK informed the MHRA of our decision to suspend the release, distribution and supply of all dose forms of Zantac products," a company spokesman confirmed to Reuters.

"GSK is continuing with investigations into the potential source of the NDMA," he said, adding that the investigations include continued engagement with its suppliers and with external laboratories to conduct tests on finished product batches of Zantac.

The Medicines and Healthcare products Regulatory Agency (MHRA) said healthcare professionals were told on Monday to "stop supplying the products immediately, quarantine all remaining stock and return it to their supplier".

"We are advising that patients should not to stop taking their medication, and do not need to see their doctor until their next routine appointment but should seek their doctor's advice if they have any concerns," the MHRA said.

GLOBAL STOPPAGE

US and European health regulators said last month they were reviewing the safety of ranitidine, after online pharmacy Valisure flagged the impurities.

The FDA said Valisure's higher-temperature testing method generated very high levels of NDMA from the ranitidine drugs.

NDMA had previously been found in some blood pressure medicines from a class of drugs known as angiotensin II receptor blockers, or ARBs.

After checking the over-the-counter drugs using a low-heat method of testing, the FDA said it found much lower levels of NDMA than was discovered with a higher temperature test employed by Valisure.

The US regulator has asked ranitidine makers to conduct their own testing to assess levels of the impurity and to send samples of their products for testing by the agency.

Swiss drugmaker Novartis halted global distribution of its ranitidine drugs last month.

Last week, Walmart Inc joined pharmacy chains CVS Health Corp, Walgreens Boots Alliance Inc and Rite Aid Corp in suspending the sale of over-the-counter heartburn drugs containing ranitidine.

Canada's health authorities have asked makers of the drugs to halt distribution as they gather more information. Last month, regulators in Hong Kong pulled four products, while in Ireland 13 products containing ranitidine were recalled.

The impurity was believed to have been introduced by changes in the manufacturing process.

source: news.abs-cbn.com

Sunday, September 29, 2019

Mexican crooner Jose Jose, hero of jilted lovers, dead at 71


MIAMI - Jose Jose, a velvety-voiced Mexican crooner who was wildly popular in Latin America over a 50-year career that spawned love song after love song, has died, the Mexican government and his son said Saturday. He was 71.

Jose Sosa Ortiz, known as the "principe de la cancion," or prince of song, had suffered from pancreatic cancer.

"We regret to report the death of singer Jose Romulo Sosa, better known as Jose Jose ... since the beginning of his career, the singer of 'El Triste' was one of the most beloved voices in Mexico," the country's Culture Ministry said on Twitter.

Son Jose Joel posted images of black ribbons on his Facebook page, saying "we are trying to process the situation by having in our heart the divine promise that we will see and hold him again, never to be separated."

Mexican broadcaster Televisa, which Jose Jose worked with for much of his career, reported that the singer died Saturday at a hospital in Homestead, Florida, near Miami.

He sold more than 120 million records during his professional life, many of them featuring songs meant to comfort jilted lovers.

In his heyday in the 1970s, 1980s and 1990s, Jose Jose churned out hit records at a dizzying pace.

His first international hit -- "La Nave del Olvido," or "The Ship of Oblivion" -- came out in 1970 and is still heard on Latin American radio stations from time to time.

"He was an extraordinary singer," Mexican President Andres Manuel Lopez Obrador said. 

"He made many people in my generation cry or feel happy with his songs," the 65-year-old leader said. "The best tribute that we can pay him is to remember and never stop listening to his songs. Some of his hits are just amazing."

Jose Jose had an interest in mysticism, and in March 2018, when he revealed to his fans that he had been diagnosed with cancer, he blamed it on what he called negative energy surrounding him.

Romances and alcoholism 

After the news of his death, fans flocked to Claveria, the middle-class neighborhood of the Mexican capital where Jose Jose grew up, to sing his best-known songs, including "El Triste."

Jose Jose was very open with the press and his fans about his personal life, including his romances and battle with alcoholism.

In 2008, he published his autobiography, entitled "Esta es mi vida," or "This is My Life," and promoted it as an inspiration for people battling addiction.

Jose Jose quit drinking in 1993, but the hard life he had led, the strain on his voice after decades of performing, and other health issues silenced his beloved tenor tones. He stopped singing in the early 2000s.

Sosa Ortiz was born in Mexico City to a family of musicians. As a small child, he got his first taste of that world by singing in school choirs.

As a teen, he performed in taverns and sang serenades until he recorded his first album in 1969. It was a smash hit.

That was when he took Jose Jose as his showbiz name, the second Jose meant to honor his father, who had died a year earlier.

The crooner married three times and fathered three children. His widow is Sara Salazar, a Cuban he married in 1995. They moved from Mexico to Miami that same year.

In an interview in January 2018 on Telemundo to promote a TV series based on his life, Jose Jose was a mere shadow of what he had been. He spoke in a weak, fragile voice, his face partially paralyzed.

Asked about love, the man who spent decades singing about it, said that throughout his life, he had never been able to stand up for himself with his lovers.

"They did absolutely whatever they wanted with me," he said.

source: news.abs-cbn.com

Tuesday, September 10, 2019

Former Empress Michiko leaves hospital after breast cancer surgery


TOKYO - Former Empress Michiko was discharged from the University of Tokyo Hospital on Tuesday, two days after undergoing successful breast cancer surgery, the Imperial Household Agency said.

Doctors deemed the 84-year-old former empress was recovering smoothly from the surgery Sunday after observing that her appetite was gradually returning and she could leave her room and walk around.

The former emperor expressed gratitude to the head of the hospital and doctors who conducted the operation, telling them "thank you" before returning to the Imperial Palace by car.

She was admitted to hospital on Saturday to undergo a partial mastectomy to remove cancerous cells while preserving her left breast.

The operation was performed by medical staff from the Shizuoka Cancer Center, which dispatched doctors to carry out breast cancer screenings of the former empress, and the University of Tokyo Hospital.

A lump was found in July in the mammary gland of the former empress's left breast during an echography exam, and the cancer diagnosis was confirmed after a needle biopsy was conducted in early August.

At stage 1, the earliest stage of invasive breast cancer out of four, no tumor cells were detected to have spread.

A decision on whether or not to administer hormone therapy and other treatments will be made based on the results of a final pathological diagnosis of the removed tissue, which will take one to two weeks to complete.

On the day of the surgery, Former Emperor Akihito and the couple's daughter Sayako Kuroda visited the hospital to see the former empress before her operation. The pair also came to the hospital on Monday.

Former Empress Michiko lost weight due to stress and a busy schedule amid the imperial succession earlier in the year, according to the agency. She underwent cataract surgery on both eyes in June and was earlier diagnosed with heart valve abnormalities, with the condition continuing to be monitored.

The former emperor became the first Japanese monarch to abdicate in about two centuries, bringing an end to the Heisei Era spanning his 30-year reign. His elder son Emperor Naruhito ascended the Chrysanthemum Throne on May 1.

==Kyodo

source: news.abs-cbn.com

Monday, September 9, 2019

Years later, cancer cases linger over 9/11 anniversary


NEW YORK - Jacquelin Febrillet was 26 years old on September 11, 2001 when jihadist hijackers flew two passenger jets into the World Trade Center just two blocks from where she worked.

Fifteen years after the attacks that day, Febrillet, by then a mother of three, was diagnosed with metastatic cancer. The likely cause: a cloud of toxic ash that engulfed her.

"I was there (on) 9/11... For years I have been working down there every day since 9/11. We were never told that something could happen," she says.

Unlike Febrillet, Richard Fahrer, then 19, wasn't in the area on 9/11, but he regularly worked as a land surveyor between 2001 and 2003 in south Manhattan, where the Twin Towers came crashing down.

Eighteen months ago, the young father, now 37, was diagnosed with aggressive colon cancer -- a disease that usually affects older men and which there is no history of in his family.

Febrillet and Fahrer represent a growing category of patient who were living or working close to the World Trade Center in the wake of the attacks, which killed almost 3,000 people.

They were not among the thousands of emergency personnel who rushed to the site or who spent months clearing debris at Ground Zero, but their health is being similarly affected.

As the 18th anniversary of the attacks approaches, New York continues to count the number of people who have developed cancer or other serious illnesses related to the toxic cloud that hovered over Manhattan for several weeks.

'PEOPLE ARE DYING'

The 9/11 attacks released unprecedented amounts of chemicals into the air, including dioxins, asbestos and other carcinogenic substances.

Firefighters, other first responders and volunteers who helped with the months-long clean-up were the first to be affected. Studies found they faced an increased risk of cancer and cardiovascular disease.

Ten thousand of them have been diagnosed with cancer by the World Trade Center Health Program, a federal treatment program helping survivors.

At the end of June this year, 21,000 people not considered first responders were also in the program -- twice as many as in June 2016. Of these, almost 4,000 have cancer, the most common being prostate, breast and skin.

Febrillet, now 44, is one of them. She recalls that the message at the time was to get the city back to normal as quickly as possible.

"People were just going about their business a few days later. But look at what happened a few years later, people are dying," says Febrillet, who also lived close to Ground Zero.

Fahrer, too, laments that city officials did not do more to protect residents and office staff in the vicinity.

"My wife asks me, 'Did terrorists cause your cancer?' I can't say 100 percent, but I do know there could have been better efforts to limit the exposure of healthy adults from entering into the disaster area," he says.

COMPENSATION FUND

Health experts say it is impossible to pinpoint exactly the cause of cancer in every patient, but note that there is a clear correlation between the rate and exposure to toxic debris.

Several studies have shown that the cancer rate "has increased between 10 and 30 percent" among people who were exposed compared to those who weren't, David Prezant, New York fire department chief medical officer, told AFP.

The rate is expected to increase further, he said, as exposed people get older. The risk of cancer increases with age and some cancers, including lung, can take 20 to 30 years to develop, Prezant added.

It is because of this that President Donald Trump signed a bill in July that extends a deadline for victims to file claims for compensation from December 2020 to 2090.

The Victim Compensation Fund will be regularly topped up after exhausting its initial budget of $7.3 billion. The average compensation per patient is $240,000, or $682,000 for a deceased person.

Lawyer Matthew Baione, who represents Fahrer and Febrillet in their pursuit of claims, said the extension recognized that it was appropriate to cover someone "who was a baby during the attacks for the rest of their life."

"We have lost so many people, so many friends are sick," says Febrillet

"You get to a point where you are not asking, 'Have you seen so and so, I wonder how she is doing, is she retired?'

"Instead you are asking, 'So how is the surgery, how is the treatment going?' We are so young, this shouldn't be happening."

cat/pdh/wd

source: news.abs-cbn.com

Thursday, August 15, 2019

Horn snail may prevent spread of cancer cells, claims UP study


MANILA - Extracts from a horn snail locally known as bagongon were found to be possibly effective in preventing the spread of cancer cells by a group of University of the Philippines Manila students.

Telescopium telescopium, used to prepare Ilonggo dish ginataang bagongon, may inhibit angiogenesis or the formation of blood vessels from pre-existing ones, according to the study of UP Manila pharmacy students.

Inhibiting the blood vessels' growth would starve the cancer cells and stop its growth.

"Restriction of the tumor growth by Telescopium telescopium maybe due to the antiangiogenic activity of the compound rather than direct tumor cell killing ability," the study read.

The horn snail's antiangiogenic activity was tested using a partially opened fertilized duck egg where the growth of the blood vessels was observed.

"Based on the results, after treatment with a certain concentration of Telescopium telescopium extract, blood vessel size and length were reduced at a significant level. Growth of new blood vessels was inhibited, thus also inhibiting angiogenesis," according to the abstract of the study from UP's Office of the Vice President for Academic Affairs.

source: news.abs-cbn.com

Thursday, July 18, 2019

Exercise in middle age tied to longer life, study says


Even if they were inactive during their younger years, middle aged and older adults who get at least the minimum recommended amount of exercise each week may live longer than their sedentary counterparts, suggests a large UK study.

Physical activity has long been linked to a lower risk of cardiovascular disease and certain cancers. But most research has looked at exercise habits at a single point in time rather than activity patterns across the years, researchers note in The BMJ.

For the current study, researchers assessed activity levels several times over eight years for 14,599 men and women who were between 40 and 80 years old at the outset. After the first eight years, researchers started tracking mortality for another 12.5 years, on average. During that period, there were 3,148 deaths, including 950 from cardiovascular disease and 1,091 from cancer.

The researchers measured both work and leisure-time physical activity in terms of energy expended per kilogram of body weight. Activity increases over time that were equivalent to going from sedentary to meeting the World Health Organization’s recommendation of at least 150 minutes a week of moderate physical activity were associated with a 24% lower risk of death from any cause, a 29% lower risk of cardiovascular death and an 11% lower risk of cancer death compared to those who remained inactive.

“This sends a strong message to all of us, irrespective of what our current life circumstances may be, since it is never too late to build physical activity into your daily routine in order to enjoy a longer healthier life,” said Soren Brage, senior author of the study and a researcher at the University of Cambridge in the UK.

“Everybody benefitted from becoming more active,” Brage said by email. “This was also true for the subgroup of people who already had a serious chronic condition such as heart disease and cancer at baseline.”

The reduced risk of death linked to increasing activity was present regardless of past activity levels and improvements or even worsening of other risk factors such as diet, body weight, medical history, blood pressure and cholesterol levels over the years.

Compared to consistently inactive people, adults who shifted from being inactive to “low” activity levels were 24% less likely to die of any causes during the study, while people who reached “medium” activity levels were 38% less likely to die and adults who achieved “high” activity levels were 42% less likely to die.

At the population level, the researchers calculated, getting at least 150 minutes a week of moderate intensity physical activity would potentially prevent 46% of deaths associated with physical inactivity.

The study wasn’t designed to prove whether or how exercise, or changes in activity over time, might directly prevent disease or help people live longer.

Even so, it adds to evidence suggesting that changing exercise habits late in life can still make a difference, said Dr. I-Min Lee, a researcher at the Harvard T.H. Chan School of Public Health and Brigham and Women’s Hospital in Boston who wasn’t involved in the study.

Other studies that randomly assigned inactive people to start exercising or maintain their current lifestyle have found, among other things, that starting to exercise can improve blood pressure, blood sugar, cholesterol levels, and inflammation and reduce belly fat, Lee said by email.

“Becoming physically active in mid-life can extend longevity,” Lee said.

SOURCE: bit.ly/2xPTOlJ The BMJ, online June 26, 2019.

Tuesday, July 9, 2019

UK offers HPV vaccines to boys, aims to stop 100,000 cancer cases


LONDON - Some 100,000 cases of cancer could be prevented in Britain in the next 40 years by a vaccine against the human papillomavirus (HPV) that causes cancers of the cervix, mouth, anus and genitals, UK health officials said on Tuesday.

Announcing the extension of a vaccination program to cover boys as well as girls, experts at Public Health England (PHE) said the immunization plan would prevent around 64,000 cervical cancers and nearly 50,000 non-cervical cancers by 2058.

This would be 50 years after the introduction of the HPV vaccination program in Britain - which began in girls in 2008 - when people who were vaccinated as teenagers might otherwise begin to develop HPV-related cancers, PHE said in a statement.

HPV is a sexually transmitted virus linked to more than 99% of cervical cancers, as well as 90% of anal cancers, about 70% of vaginal and vulvar cancers and more than 60% of penile cancers.

PHE said that from September this year boys aged 12 and 13 in Britain will be offered the shots as part of a government health program.

Since UK girls began getting the HPV vaccine in 2008, studies have shown that infections with some key types of the virus have fallen by 86% in 16 to 21 year-olds in England. A Scottish study also showed the vaccine had reduced pre-cancerous cervical disease in women by up to 71%.

Robin Weiss, a professor of viral oncology at University College London, said the extension of the HPV program "should be a win-win situation".

"The HPV vaccine has enjoyed 10 years of success in protecting girls from acquiring cervical cancer as women," he said in an emailed comment. "It appears clear ... that vaccinated boys will themselves benefit from not getting cancer of the penis, anus, and a diminished risk of head and neck cancer." 

source: news.abs-cbn.com

Sunday, May 12, 2019

Boxing: Popular broadcaster Lederman dies at 79


LOS ANGELES -- Respected boxing judge turned broadcaster Harold Lederman, best known as the unofficial scorekeeper for HBO Boxing, has died at 79 after battling cancer, veteran promoter Lou DiBella said Saturday.

Lederman began his career as a boxing judge in 1967 and joined the cast of HBO World Championship Boxing in 1986.

His death comes less than six months after he worked the final card on HBO, to cap the cable television network's 40-year run in the sport.

"Just learned that my friend of 30 years, Harold Lederman, has succumbed to the cancer he fought so hard," DiBella said on Twitter, adding that Lederman "was one of a kind & there will never be another".

His praise for the knowledgeable and always ebullient Lederman was echoed by figures throughout the boxing world, and by Lederman's former colleagues at HBO.

"Harold Lederman had a lifelong love affair with the sport of boxing," Peter Nelson, executive vice president of HBO Sports said in a statement. "Over the past fifty years he was universally respected and celebrated by the many people who make the sport what it is.

"Harold was happiest when seated ringside, studying the action and scoring the fight. When he joined HBO Sports in 1986 he added a new and critical component to live boxing coverage.

"Viewers embraced his unique style and his command of the rules while his broadcast colleagues relished his enthusiasm and boundless energy."

Lederman earned his license from the New York State Athletic Commission to judge title fights on June 26, 1967.

He judged more than 100 title fights while maintaining his pharmacy practice in New York.

His commentating career began before he retired from active judging in 1999, and his detailed explanations of how he analyzed and scored bouts were a key feature of HBO's boxing telecasts.

"No one in the sport had more friends, because no one in the sport was more deserving of friends," said HBO boxing announcer Jim Lampley in a statement.

Lederman was inducted into the International Boxing Hall of Fame in 2016. His daughter Julie Lederman followed in his footsteps and became a boxing judge.

source: news.abs-cbn.com

Friday, April 5, 2019

Canada to ban breast implants linked to rare cancer


OTTAWA - Canada said Thursday it aims to soon suspend the sales in this country a type of breast implant that has been linked to a rare form of cancer.

The announcement comes after France banned the types of implants with a textured surface or polyurethane coating, and after the US Food and Drug Administration (FDA) last month held two days of hearings on their risks.

Health Canada said it was a "precautionary measure" following a safety review triggered by a spike in cases of anaplastic large cell lymphoma (BIA-ALCL), a rare type of cancer that attacks the immune system, linked to the implants.

The agency noted 28 cases in Canada -- out of 457 recorded worldwide, according to the FDA.

The only distributor of textured implants in this country, US manufacturer Allergan, has 15 days to provide new evidence to support their continued use. 

Otherwise its licenses will be suspended and "the product will no longer be permitted to be sold in Canada," said a statement.

Silicone implants are used in breast enhancements, or for reconstructive purposes after a mastectomy for breast cancer. They can either be smooth, textured or coated in polyurethane. 

The popular textured implants are designed to stick to the breast tissue to avoid slipping out of position.

Some studies suggest that inflammation caused by the textured implants rubbing against breast tissue could cause BIA-ALCL.

Several implant wearers have already launched legal action against Allergan, accusing it of "deliberately endangering the lives of others."

Polyurethane-coated implants are not sold in Canada.

amc/ia

source: news.abs-cbn.com

Tuesday, March 19, 2019

Short walk once-a-week can lower risk of death: study


PARIS, France - A brisk stroll once or twice a week is enough to reduce the risk of dying from heart attack, stroke or cancer, according to a statistical study of nearly 90,000 people released Tuesday.

People who walked or gardened 10 minutes to an hour each week had an 18-percent lower risk of death from any cause compared to full-on couch potatoes, researchers reported in the British Journal of Sports Medicine.

Two-and-a-half to five hours weekly of such "moderate physical activity" -- broken into segments of no less than 10 minutes -- resulted in a 31 percent reduction in risk, they found.

And those who clocked up at least 25 hours almost halved the risk.

Not everyone, however, has that much time to spend on leisure-time exercise, the authors acknowledged.

Heart-pumping and pulse-quickening activities such as biking, running and competitive sports "are more time-efficient than moderate intensity activity," they said.

For cardiovascular disease alone, there was no additional benefit to be gained by graduating from five to 25 hours, they noted.

Researchers led by Bo Xi, a professor in the Department of Epidemiology at Shandong University in northern China, sifted through data collected annually on 88,140 people in the United States between 1997 and 2008 for the National Health Interview Surveys.

That data on exercise was then matched against registered deaths through 2011.

The authors cautioned that the study was observational, meaning that no firm conclusions can be drawn about cause and effect. The fact that exercise data was self-reported was also a potential weakness.

But the large number of people covered by the research goes a long way to compensate for these methodological limitations, they added.

mh/nla

source: news.abs-cbn.com

Friday, March 8, 2019

E-cigarette use linked to heart trouble: study


People who use e-cigarettes are more likely to have heart problems than those who don't, says a study released on Thursday in the US.

The rate of heart attacks among those who vape was 34 percent higher than among those who don't, once corrections were made for risk factors such as age, gender, body mass index, cholesterol level, blood pressure and tobacco use.

E-cigarette users were 25 percent more likely to have coronary artery disease and 55 percent more likely to suffer from depression or anxiety, the study says.

"Until now, little has been known about cardiovascular events relative to e-cigarette use," said Mohinder Vindhyal, assistant professor at the University of Kansas School of Medicine and the study's lead author.

"These data are a real wake-up call and should prompt more action and awareness about the dangers of e-cigarettes."

The report does not however identify a cause and effect relationship for this observation.

Studies of people who vape are relatively new because the devices only came onto the US market in the last decade or so.

US health authorities are alarmed by the rise in popularity of e-cigarettes, battery-powered devices which enable users to inhale nicotine liquids that are often fruit flavored.

Among US teens, use of vaping devices rose 78 percent in 2018 compared to the previous year.

E-cigarettes do not contain the cancer-causing products found in tobacco.

But beside the well-known addictive consequences of consuming nicotine, public health experts are focusing on the effect of heating the liquid nicotine cartridges to high temperatures.

For the study, which will be presented next week at the American College of Cardiology, researchers examined the responses of nearly 100,000 people in 2014, 2016 and 2017.

This kind of study is a preliminary one that does not go so far as to say vaping causes heart trouble, or suggest a biological mechanism as to how this might happen.

Longer-term studies of people who vape are needed to reach any such conclusion.

source: news.abs-cbn.com

Monday, January 7, 2019

Eli Lilly to acquire Loxo Oncology for $8 billion


WASHINGTON - Pharmaceutical giant Eli Lilly will acquire cancer treatment specialist Loxo Oncology in a cash deal valued at around $8 billion, the companies said on Monday.

The firms "announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion," a statement said.

The deal -- which represents a premium of some 68 percent over Loxo Oncology's closing share price on Friday -- is expected to close by the end of the first quarter, the statement said.

The announcement is the latest in a series of major pharmaceutical deals: last week, Bristol-Myers Squibb said it would buy biotech firm Celgene in a $74 billion cash-and-stock agreement, creating a rival to the world's largest drug makers.

Other recent large pharma deals include French company Sanofi's purchase of US hemophilia group Bioverativ for $11.6 billion and Novartis' $8.7 billion acquisition of rare-disease treatment company AveXis.

source: news.abs-cbn.com